Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1Breast 1

Conditions

Neutropenia 1Chemotherapy-Induced Febrile Neutropenia 1Breast Neoplasms 1

Interventions

Epoetin Alfa 6olaparib 5pegfilgrastim 3Filgrastim 3Carboplatin 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2abemaciclib 2Tretinoin 2venetoclax 1trametinib 1talazoparib 1stinging nettle lectin 1ruxolitinib 1ribociclib 1regorafenib 1ponatinib 1pertuzumab 1peppermint oil 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × MYL-1401H × Classical hematology × Clear all
NCT02467868 2022-02-14

Efficacy and Safety Study With MYL-1401H and Neulasta

Viatris Inc.

Phase 3 Completed
193 enrolled
BreastClassical hematology

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡